Review highlights the pathological significance of CEACAM1, 5, and 6

A new review was published in Genes & Cancer on February 1, 2023, entitled, "CEACAMS 1, 5, and 6 in disease and cancer: interactions with pathogens."

"Carcinoembryonic antigen (CEA), one of few FDA-approved biomarkers for cancer, was first identified and described in 1965 as a tumor-specific antigen expressed in embryonic gut, liver, and pancreas tissues, as well as gastrointestinal and respiratory malignancies, but not in differentiated adult tissues [1]."

The CEA family comprises 18 genes and 11 pseudogenes located at chromosome 19q13.2 and is divided into two main groups: cell surface anchored CEA-related cell adhesion molecules (CEACAMs) and the secreted pregnancy-specific glycoproteins (PSGs). CEACAMs are highly glycosylated cell surface anchored, intracellular, and intercellular signaling molecules with diverse functions, from cell differentiation and transformation to modulating immune responses associated with infection, inflammation, and cancer.

In this review, researchers Jerin Thomas, Addison Klebanov, Sahara John, Larry S. Miller, Anil Vegesna, Richard L. Amdur, Krishanu Bhowmick, and Lopa Mishra from the Donald and Barbara Zucker School of Medicine, Feinstein Institutes for Medical Research at Northwell Health, and Cold Spring Harbor Laboratory explored current knowledge surrounding CEACAM1, CEACAM5, and CEACAM6, highlight their pathological significance in the areas of cancer biology, immunology and inflammatory disease, and describe the utility of murine models in exploring questions related to these proteins.

"CEACAM1, 5, and 6 have shown their importance in gastrointestinal pathologies as they are closely involved with immune regulation, tumorigenesis, tumor suppression, and pathogen binding. Interrupting the interactions of CEACAM family members seems to be an interesting avenue of research, as it may be a useful tool in cancer therapy, and regulating immune activity in the context of IBD. However, much work has yet to be done in regard to the role of CEACAMs in cellular signaling and their effects on microbiome regulation."

Source:
Journal reference:

Thomas, J., et al. (2023) CEACAMS 1, 5, and 6 in disease and cancer: interactions with pathogens. Genes & Cancer. doi.org/10.18632/genesandcancer.230.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New Method for Identifying Kinase Inhibitors for Cancer Therapy